Merck reaches weight-loss drug deal worth up to $2 billion

Merck signs up to $2 billion deal for oral weight-loss drug with China's Hansoh
U.S. drugmaker Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharmaceuticals to develop and commercialize the Chinese biotech's experimental obesity drug.
Merck reaches weight-loss drug deal worth up to $2 billion with China-based Hansoh
Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named HS-10535. It includes a $112 million licensing rights payment for global sales outside China.
Merck moves into obesity with deal for Hansoh’s GLP-1 pill
News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen as likely buyout targets.
Merck Makes Another Play for Lucrative Obesity-Drug Market
Merck & Co. is doubling down on getting into the white-hot weight-loss drug market, scooping up a pill developed in China. Merck said Wednesday it will pay Hansoh Pharma $112 million upfront for the rights to develop,
Merck Snags Chinese Obesity Drug in Nearly $2 Billion Deal
Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.
Merck, Hansoh Pharma in Obesity Pill License Potentially Worth More Than $2 Billion
Merck & Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company. Merck on Wednesday said it will make an upfront payment of $112 million to Hansoh in exchange for an exclusive global license to HS-10535,
Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in payments and royalties on sales.
Merck Strikes Deal With China's Hansoh Pharma to Develop Weight Loss Drug
Merck (MRK) secured exclusive rights to develop and sell an oral weight loss drug under a license deal with Hansoh Pharma that could fetch the Chinese biopharmaceutical company up to $2 billion. Merck agreed to pay $112 million up front to Hansoh Pharma,
Pharmalittle: We’re reading about a Merck deal for an obesity pill, a departing FDA official, and more
Merck signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's oral obesity drug
Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows
About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.
Down 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck?
The weight-loss biotech Viking Therapeutics (NASDAQ: VKTX) saw its stock get absolutely slammed on Dec. 18, falling 18% as a ...
FiercePharma2d
Mirroring Merck's problem, GSK's Jemperli-Zejula study in ovarian cancer misses survival goal
Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...
Merck Has Become Very Cheap Again
Merck has become inexpensive again and combines a good growth outlook with a nice and growing dividend. Learn why MRK stock ...
Merck discontinues development of 2 experimental cancer drugs after trial failures
Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several ...
Strategic Moves in Cardiometabolic Space: Merck’s Buy Rating for Innovative Combination Therapies
Jefferies analyst Akash Tewari has maintained their bullish stance on MRK stock, giving a Buy rating on December 18.Pick the best stocks and ...
Merck calls quits on two immunotherapies for cancer
The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 ...
Merck's HIV treatment meets main goal in two late-stage studies
Merck's experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in ...